HK Stock MarketDetailed Quotes

01877 JUNSHI BIO

Watchlist

13.560
-0.160-1.17%

Trading Dec 3 09:30 CST

13.37BMarket Cap-6689P/E (TTM)

JUNSHI BIO Stock Forum

Moomoo AI

Mar 5 16:54

The company's weak revenue trend, unprofitability, and rapid decline in share price reflect poor fundamentals. Last year's performance indicates unresolved challenges, worse than the annualized loss of 9% over the last half decade.

Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%

Spinee

Jan 17 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Moomoo AI

Jan 8 19:54

Despite Shanghai Junshi Biosciences' weak revenue growth, its P/S ratio aligns with industry peers, indicating investors may be overlooking limited growth expectations and paying a premium. However, this could risk investments as the weak revenue outlook may eventually impact share prices.

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Out Of Tune With Revenues

Moomoo AI

Oct 27, 2023 19:26

Shanghai Junshi Biosciences carries rising debt yet has surplus liquid assets, offsetting risk. Despite having net cash, being a loss-maker might impact its financial health. Be cautious of investing until positive cash flow is seen.

Is Shanghai Junshi Biosciences (HKG:1877) Weighed On By Its Debt Load?

ETFWorldSavior

Jun 7, 2023 21:42

Columns Anxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released

Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...

ee071002

Feb 8, 2023 19:37

$JUNSHI BIO (01877.HK)$ good time to buy?

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data